{"id":89245,"date":"2024-02-26T14:13:00","date_gmt":"2024-02-26T17:13:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/"},"modified":"2024-02-26T14:13:00","modified_gmt":"2024-02-26T17:13:00","slug":"neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/","title":{"rendered":"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras"},"content":{"rendered":"<p><b>PR NEWSWIRE<\/b><\/p>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li><i>A coopera\u00e7\u00e3o aproveita a plataforma l\u00edder de descoberta de cola molecular da Neomorph e a ampla experi\u00eancia da Novo Nordisk em doen\u00e7as cardiometab\u00f3licas e raras <\/i><\/li>\n<li><i>Valor potencial total do neg\u00f3cio de <span class=\"xn-money\">US$ 1,46<\/span> bilh\u00e3o em diversos objetivos<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SAN DIEGO<\/span><\/span>, <span class=\"legendSpanClass\">26 de fevereiro de 2024<\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=pt&amp;o=4093298-1&amp;h=2988843988&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4093298-1%26h%3D2571170734%26u%3Dhttps%253A%252F%252Fneomorph.com%252Findex.html%2523home%26a%3DNeomorph%252C%2BInc.&amp;a=Neomorph%2C+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">Neomorph, Inc.<\/a> anunciou hoje que assinou um contrato de coopera\u00e7\u00e3o e licenciamento com a empresa internacional de sa\u00fade Novo Nordisk para descobrir, desenvolver e comercializar degradadores de cola molecular. A Neomorph, uma empresa de biotecnologia que soluciona problemas cr\u00edticos na sa\u00fade humana atrav\u00e9s da descoberta de novas terapias contra alvos &#8220;invenc\u00edveis&#8221;, foi fundada em 2020 e tem o apoio da Deerfield Management Company.<\/p>\n<div id=\"prni_dvprnejpg6d33left\" dir=\"ltr\" style=\"width: 100%;text-align: left\"><img decoding=\"async\" id=\"prnejpg6d33left\" title=\"Neomorph logo\" src=\"https:\/\/mma.prnewswire.com\/media\/2341384\/Neomorph_Logo.jpg\" alt=\"Neomorph logo\" align=\"middle\" \/><\/div>\n<p>&#8220;Estamos extremamente empolgados com a parceria com a Novo Nordisk, uma empresa de sa\u00fade de classe mundial voltada para diabetes, obesidade e doen\u00e7as sangu\u00edneas raras&#8221;, disse <span class=\"xn-person\">Phil Chamberlain<\/span>, DPhil, Cofundador, Presidente e Diretor Executivo da Neomorph. &#8220;Ao combinar a plataforma da descoberta de cola de propriedade da Neomorph com a ampla experi\u00eancia da Novo Nordisk em doen\u00e7as cardiometab\u00f3licas e raras, estamos bem posicionados para desenvolver tratamentos transformadores nestas \u00e1reas. Esta coopera\u00e7\u00e3o permitir\u00e1 a expans\u00e3o de nossa plataforma para novas \u00e1reas terap\u00eauticas, que complementam nossos esfor\u00e7os cont\u00ednuos em oncologia.&#8221;<\/p>\n<p>Segundo os termos do contrato, a Neomorph ir\u00e1 receber pagamentos antecipados e a curto prazo, al\u00e9m de financiamento para pesquisa e desenvolvimento. A Neomorph tamb\u00e9m \u00e9 eleg\u00edvel para receber pagamentos futuros por marcos cl\u00ednicos, comerciais e de vendas, elevando o valor potencial total do neg\u00f3cio para diversos objetivos a <span class=\"xn-money\">US$ 1,46<\/span> bilh\u00e3o, mais royalties escalonados. A Neomorph ir\u00e1 liderar atividades de descoberta e pr\u00e9-cl\u00ednicas contra objetivos selecionados, com a Novo Nordisk tendo o direito de prosseguir exclusivamente o desenvolvimento cl\u00ednico e a comercializa\u00e7\u00e3o dos compostos.<\/p>\n<p>&#8220;A Novo Nordisk est\u00e1 expandindo seus esfor\u00e7os de descoberta de medicamentos e implementando uma s\u00e9rie de novas plataformas tecnol\u00f3gicas, visando descobrir e desenvolver novas solu\u00e7\u00f5es de tratamento para pessoas que vivem com doen\u00e7as cr\u00f4nicas graves. Temos o prazer de participar desta coopera\u00e7\u00e3o de pesquisa e ansiosos para iniciar o trabalho cient\u00edfico na nova classe de degradadores de cola moleculares lan\u00e7ada pela Neomorph&#8221;, disse <span class=\"xn-person\">Brian Vandahl<\/span>, Vice-Presidente S\u00eanior de Tecnologias de Pesquisa Global da Novo Nordisk.<\/p>\n<p><b>Sobre a Neomorph<\/b>\u00a0<br \/>A Neomorph \u00e9 uma empresa de biotecnologia que soluciona problemas cr\u00edticos da sa\u00fade humana mediante a descoberta e o desenvolvimento de novos medicamentos inovadores contra alvos &#8220;invenc\u00edveis&#8221;. A Neomorph foi fundada em 2020 e tem o apoio da Deerfield Management Company.<\/p>\n<p>A equipe da Neomorph \u00e9 composta por especialistas l\u00edderes do setor em degrada\u00e7\u00e3o de prote\u00ednas e colas moleculares que possuem um hist\u00f3rico de descobertas inovadoras na \u00e1rea. A equipe da Neomorph est\u00e1 comprometida com a lideran\u00e7a no avan\u00e7o da ci\u00eancia e da tecnologia na descoberta de medicamentos para cola molecular, enquanto desenvolve uma s\u00e9rie de projetos atrav\u00e9s do desenvolvimento cl\u00ednico.<\/p>\n<p>A Neomorph tem sede em <span class=\"xn-location\">San Diego<\/span>, Calif\u00f3rnia. Para mais informa\u00e7\u00e3o, acesse <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=pt&amp;o=4093298-1&amp;h=3190740563&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4093298-1%26h%3D931005466%26u%3Dhttp%253A%252F%252Fwww.neomorph.com%252F%26a%3Dwww.neomorph.com&amp;a=www.neomorph.com\" target=\"_blank\" rel=\"nofollow noopener\">www.neomorph.com<\/a>\u00a0e siga-nos no <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=pt&amp;o=4093298-1&amp;h=3534503531&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4093298-1%26h%3D3321162102%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fneomorph-llc%252Fmycompany%252F%26a%3DLinkedIn&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>.<\/p>\n<p><b>Contatos<\/b>\u00a0<br \/>Contato do Investidor: <a href=\"mailto:inquiries@neomorph.com\" target=\"_blank\" rel=\"nofollow noopener\">inquiries@neomorph.com<\/a>\u00a0<br \/>Contato de M\u00eddia: <a href=\"mailto:media@neomorph.com\" target=\"_blank\" rel=\"nofollow noopener\">media@neomorph.com<\/a>\u00a0<\/p>\n<p>Logotipo &#8211; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=pt&amp;o=4093298-1&amp;h=3076207706&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4093298-1%26h%3D3024849545%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F2341384%252FNeomorph_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F2341384%252FNeomorph_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2341384%2FNeomorph_Logo.jpg\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/mma.prnewswire.com\/media\/2341384\/Neomorph_Logo.jpg<\/a><\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PT38208&amp;sd=2024-02-26\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/br\/comunicados-para-a-imprensa\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras-302070213.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/br\/comunicados-para-a-imprensa\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras-302070213.html<\/a><\/p>\n<p>FONTE  Neomorph<\/p>\n<\/div>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT38208&amp;Transmission_Id=202402261206PR_NEWS_LATAM____PT38208&amp;DateId=20240226\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n<p>A <b>OESP<\/b> n\u00e3o \u00e9(s\u00e3o) respons\u00e1vel(is) por erros, incorre\u00e7\u00f5es, atrasos ou quaisquer decis\u00f5es tomadas por seus clientes com base nos Conte\u00fados ora disponibilizados, bem como tais Conte\u00fados n\u00e3o representam a opini\u00e3o da <b>OESP<\/b> e s\u00e3o de inteira responsabilidade da <b>PR Newswire Ltda<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"PR NEWSWIRE A coopera\u00e7\u00e3o aproveita a plataforma l\u00edder de descoberta de cola molecular da Neomorph e a ampla experi\u00eancia da Novo Nordisk em doen\u00e7as cardiometab\u00f3licas e raras Valor potencial total","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[28],"tags":[],"class_list":["post-89245","post","type-post","status-publish","format-standard","hentry","category-prnewsbrasil"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras - Ag\u00eancia de Comunica\u00e7\u00e3o<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras - Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"og:description\" content=\"PR NEWSWIRE A coopera\u00e7\u00e3o aproveita a plataforma l\u00edder de descoberta de cola molecular da Neomorph e a ampla experi\u00eancia da Novo Nordisk em doen\u00e7as cardiometab\u00f3licas e raras Valor potencial total\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/\" \/>\n<meta property=\"og:site_name\" content=\"Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-26T17:13:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2341384\/Neomorph_Logo.jpg\" \/>\n<meta name=\"author\" content=\"patric_oliveira\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"patric_oliveira\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/\"},\"author\":{\"name\":\"patric_oliveira\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"headline\":\"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras\",\"datePublished\":\"2024-02-26T17:13:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/\"},\"wordCount\":644,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2341384\\\/Neomorph_Logo.jpg\",\"articleSection\":[\"PR Newswire Brasil\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/\",\"name\":\"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras - Ag\u00eancia de Comunica\u00e7\u00e3o\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2341384\\\/Neomorph_Logo.jpg\",\"datePublished\":\"2024-02-26T17:13:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2341384\\\/Neomorph_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2341384\\\/Neomorph_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsbrasil\\\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\",\"name\":\"Ag\u00eancia de Comunica\u00e7\u00e3o\",\"description\":\"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\",\"name\":\"patric_oliveira\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"caption\":\"patric_oliveira\"},\"sameAs\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"],\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/author\\\/patric_oliveira\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras - Ag\u00eancia de Comunica\u00e7\u00e3o","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/","og_locale":"pt_BR","og_type":"article","og_title":"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras - Ag\u00eancia de Comunica\u00e7\u00e3o","og_description":"PR NEWSWIRE A coopera\u00e7\u00e3o aproveita a plataforma l\u00edder de descoberta de cola molecular da Neomorph e a ampla experi\u00eancia da Novo Nordisk em doen\u00e7as cardiometab\u00f3licas e raras Valor potencial total","og_url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/","og_site_name":"Ag\u00eancia de Comunica\u00e7\u00e3o","article_published_time":"2024-02-26T17:13:00+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2341384\/Neomorph_Logo.jpg","type":"","width":"","height":""}],"author":"patric_oliveira","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"patric_oliveira","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/#article","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/"},"author":{"name":"patric_oliveira","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"headline":"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras","datePublished":"2024-02-26T17:13:00+00:00","mainEntityOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/"},"wordCount":644,"commentCount":0,"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2341384\/Neomorph_Logo.jpg","articleSection":["PR Newswire Brasil"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/","name":"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras - Ag\u00eancia de Comunica\u00e7\u00e3o","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/#primaryimage"},"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2341384\/Neomorph_Logo.jpg","datePublished":"2024-02-26T17:13:00+00:00","author":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"breadcrumb":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2341384\/Neomorph_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2341384\/Neomorph_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsbrasil\/neomorph-anuncia-cooperacao-multialvo-com-a-novo-nordisk-para-descobrir-novos-degradadores-de-cola-molecular-para-doencas-cardiometabolicas-e-raras\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"},{"@type":"ListItem","position":2,"name":"Neomorph anuncia coopera\u00e7\u00e3o multialvo com a Novo Nordisk para descobrir novos degradadores de cola molecular para doen\u00e7as cardiometab\u00f3licas e raras"}]},{"@type":"WebSite","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/","name":"Ag\u00eancia de Comunica\u00e7\u00e3o","description":"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37","name":"patric_oliveira","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","caption":"patric_oliveira"},"sameAs":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"],"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/author\/patric_oliveira\/"}]}},"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/89245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=89245"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/89245\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=89245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=89245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=89245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}